{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:52:13Z","timestamp":1791546733968,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["FONDECYT 1211821"],"award-info":[{"award-number":["FONDECYT 1211821"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32888-w","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:45:08Z","timestamp":1766828708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Alpha-synuclein amyloids catalyze the degradation of ATP and other nucleotides"],"prefix":"10.1038","volume":"16","author":[{"given":"Claudio","family":"Castillo-C\u00e1ceres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Nova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Diaz-Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"32888_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","volume":"86","author":"F Chiti","year":"2017","unstructured":"Chiti, F. & Dobson, C. M. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 86, 27\u201368 (2017).","journal-title":"Annu. Rev. Biochem."},{"key":"32888_CR2","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1039\/C9CS00199A","volume":"49","author":"P Chun Ke","year":"2020","unstructured":"Chun Ke, P. et al. Half a century of amyloids: past, present and future. Chem. Soc. Rev. 49, 5473\u20135509 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"32888_CR3","doi-asserted-by":"crossref","first-page":"a023572","DOI":"10.1101\/cshperspect.a023572","volume":"9","author":"R Riek","year":"2017","unstructured":"Riek, R. The three-dimensional structures of amyloids. Cold Spring Harb Perspect. Biol. 9, a023572 (2017).","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"32888_CR4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","volume":"58","author":"JE Galvin","year":"2001","unstructured":"Galvin, J. E., Lee, V. M. Y. & Trojanowski, J. Q. Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186\u2013190 (2001).","journal-title":"Arch. Neurol."},{"key":"32888_CR5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41591-024-03469-7","volume":"31","author":"C Soto","year":"2025","unstructured":"Soto, C. et al. Toward a biological definition of neuronal and glial synucleinopathies. Nat. Med. 31, 396\u2013408 (2025).","journal-title":"Nat. Med."},{"key":"32888_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrg1831","volume":"7","author":"MJ Farrer","year":"2006","unstructured":"Farrer, M. J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306\u2013318 (2006).","journal-title":"Nat. Rev. Genet."},{"key":"32888_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12264-012-1050-z","volume":"28","author":"R Xia","year":"2012","unstructured":"Xia, R. & Mao, Z. H. Progression of motor symptoms in parkinson\u2019s disease. Neurosci. Bull. 28, 39\u201348 (2012).","journal-title":"Neurosci. Bull."},{"key":"32888_CR8","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer, R. F. Non-motor symptoms in parkinson\u2019s disease. Parkinsonism Relat. Disord. 22, S119\u2013S122 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"32888_CR9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"S Ramesh","year":"2023","unstructured":"Ramesh, S., Arachchige, A. S. P. M., Ramesh, S. & Arachchige, A. S. P. M. Depletion of dopamine in parkinson\u2019s disease and relevant therapeutic options: A review of the literature. AIMSN 10, 200\u2013231 (2023).","journal-title":"AIMSN"},{"key":"32888_CR10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-Synuclein in lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"32888_CR11","doi-asserted-by":"crossref","first-page":"10328","DOI":"10.1073\/pnas.1604645113","volume":"113","author":"P Flagmeier","year":"2016","unstructured":"Flagmeier, P. et al. Mutations associated with Familial parkinson\u2019s disease alter the initiation and amplification steps of \u03b1-synuclein aggregation. Proc. Natl. Acad. Sci. U S A. 113, 10328\u201310333 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"32888_CR12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/jnc.14707","volume":"150","author":"AT Marvian","year":"2019","unstructured":"Marvian, A. T., Koss, D. J., Aliakbari, F., Morshedi, D. & Outeiro, T. F. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies. J. Neurochem. 150, 535\u2013565 (2019).","journal-title":"J. Neurochem."},{"key":"32888_CR13","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis, L. \u03b1-Synuclein in parkinson\u2019s disease. Cold Spring Harb Perspect. Med. 2, a009399 (2012).","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"32888_CR14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0896-6273(03)00684-6","volume":"40","author":"JL Eriksen","year":"2003","unstructured":"Eriksen, J. L., Dawson, T. M., Dickson, D. W. & Petrucelli, L. Caught in the act: \u03b1-synuclein is the culprit in parkinson\u2019s disease. Neuron 40, 453\u2013456 (2003).","journal-title":"Neuron"},{"key":"32888_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-019-0095-3","volume":"5","author":"BA Killinger","year":"2019","unstructured":"Killinger, B. A., Melki, R., Brundin, P. & Kordower, J. H. Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let\u2019s talk about the lipids in the room. Npj Parkinsons Dis. 5, 1\u20138 (2019).","journal-title":"Npj Parkinsons Dis."},{"key":"32888_CR16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco, G. et al. Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Science 358, 1440\u20131443 (2017).","journal-title":"Science"},{"key":"32888_CR17","doi-asserted-by":"crossref","first-page":"11750","DOI":"10.1523\/JNEUROSCI.0234-12.2012","volume":"32","author":"MJ Di\u00f3genes","year":"2012","unstructured":"Di\u00f3genes, M. J. et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 11750\u201311762 (2012).","journal-title":"J. Neurosci."},{"key":"32888_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nbd.2015.06.003","volume":"82","author":"KL Paumier","year":"2015","unstructured":"Paumier, K. L. et al. Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 82, 185\u2013199 (2015).","journal-title":"Neurobiol. Dis."},{"key":"32888_CR19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J. Exp. Med. 209, 975\u2013986 (2012).","journal-title":"J. Exp. Med."},{"key":"32888_CR20","doi-asserted-by":"crossref","first-page":"10154","DOI":"10.1523\/JNEUROSCI.5311-12.2013","volume":"33","author":"DI Dryanovski","year":"2013","unstructured":"Dryanovski, D. I. et al. Calcium entry and \u03b1-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 33, 10154\u201310164 (2013).","journal-title":"J. Neurosci."},{"key":"32888_CR21","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"L Devi","year":"2008","unstructured":"Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G. & Anandatheerthavarada, H. K. Mitochondrial import and accumulation of \u03b1-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain *. J. Biol. Chem. 283, 9089\u20139100 (2008).","journal-title":"J. Biol. Chem."},{"key":"32888_CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/genes8120377","volume":"8","author":"G Faustini","year":"2017","unstructured":"Faustini, G. et al. Mitochondria and ?-Synuclein: friends or foes in the pathogenesis of parkinson\u2019s disease? Genes 8, 377 (2017).","journal-title":"Genes"},{"key":"32888_CR23","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann, M. H. R. et al. \u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in parkinson\u2019s disease. Nat. Commun. 9, 2293 (2018).","journal-title":"Nat. Commun."},{"key":"32888_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell, A. M. & Youle, R. J. The roles of PINK1, Parkin, and mitochondrial fidelity in parkinson\u2019s disease. Neuron 85, 257\u2013273 (2015).","journal-title":"Neuron"},{"key":"32888_CR25","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.3390\/nano12213802","volume":"12","author":"R Diaz-Espinoza","year":"2022","unstructured":"Diaz-Espinoza, R. Catalytically active amyloids as future bionanomaterials. Nanomaterials 12, 3802 (2022).","journal-title":"Nanomaterials"},{"key":"32888_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cbpa.2021.06.010","volume":"64","author":"LR Marshall","year":"2021","unstructured":"Marshall, L. R. & Korendovych, I. V. Catalytic amyloids: is misfolding folding? Curr. Opin. Chem. Biol. 64, 145\u2013153 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"32888_CR27","doi-asserted-by":"crossref","unstructured":"Arad, E. & Jelinek, R. Catalytic amyloids. Trends in Chemistry (2022).","DOI":"10.1016\/j.trechm.2022.07.001"},{"key":"32888_CR28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A. & Higgins, G. A. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256, 184\u2013185 (1992).","journal-title":"Science"},{"key":"32888_CR29","first-page":"908","volume":"1","author":"E Arad","year":"2021","unstructured":"Arad, E., Baruch Leshem, A. & Rapaport, H. Jelinek, R. \u03b2-Amyloid fibrils catalyze neurotransmitter degradation. Chem. Catal. 1, 908\u2013922 (2021).","journal-title":"Chem. Catal."},{"key":"32888_CR30","doi-asserted-by":"publisher","unstructured":"Amyloid Fibers of. \u03b1-synuclein catalyze chemical reactions | ACS chemical neuroscience. https:\/\/pubs-acs-org.ezproxy.usach.cl\/doi\/https:\/\/doi.org\/10.1021\/acschemneuro.2c00799","DOI":"10.1021\/acschemneuro.2c00799"},{"key":"32888_CR31","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.3390\/ijms241612849","volume":"24","author":"I Horvath","year":"2023","unstructured":"Horvath, I., Mohamed, K. A., Kumar, R. & Wittung-Stafshede, P. Amyloids of \u03b1-synuclein promote chemical transformations of neuronal cell metabolites. Int. J. Mol. Sci. 24, 12849 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"32888_CR32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/acschemneuro.4c00461","volume":"16","author":"I Horvath","year":"2025","unstructured":"Horvath, I. et al. Biological amyloids chemically damage DNA. ACS Chem. Neurosci. 16, 355\u2013364 (2025).","journal-title":"ACS Chem. Neurosci."},{"key":"32888_CR33","doi-asserted-by":"crossref","first-page":"129729","DOI":"10.1016\/j.bbagen.2020.129729","volume":"1865","author":"C Castillo-Caceres","year":"2021","unstructured":"Castillo-Caceres, C. et al. Functional characterization of the ATPase-like activity displayed by a catalytic amyloid. Biochim. Et Biophys. Acta (BBA)-General Subj. 1865, 129729 (2021).","journal-title":"Biochim. Et Biophys. Acta (BBA)-General Subj."},{"key":"32888_CR34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.bbrc.2016.12.011","volume":"482","author":"O Monasterio","year":"2017","unstructured":"Monasterio, O., Nova, E. & Diaz-Espinoza, R. Development of a novel catalytic amyloid displaying a metal-dependent ATPase-like activity. Biochem. Biophys. Res. Commun. 482, 1194\u20131200 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"32888_CR35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0165-0270(83)90042-0","volume":"8","author":"J Fukuda","year":"1983","unstructured":"Fukuda, J., Fujita, Y. & Ohsawa, K. ATP content in isolated mammalian nerve cells assayed by a modified luciferin-luciferase method. J. Neurosci. Methods. 8, 295\u2013302 (1983).","journal-title":"J. Neurosci. Methods"},{"key":"32888_CR36","first-page":"1","volume":"81","author":"L Dai","year":"2024","unstructured":"Dai, L. et al. Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies. Cell. Mol. Life Sci. 81, 1\u201319 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"32888_CR37","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1038\/s41467-022-32625-1","volume":"13","author":"YX Xie","year":"2022","unstructured":"Xie, Y. X. et al. Lysosomal exocytosis releases pathogenic \u03b1-synuclein species from neurons in synucleinopathy models. Nat. Commun. 13, 4918 (2022).","journal-title":"Nat. Commun."},{"key":"32888_CR38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2174\/138945012800564095","volume":"13","author":"L Antonioli","year":"2012","unstructured":"Antonioli, L. et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr. Drug Targets. 13, 842\u2013862 (2012).","journal-title":"Curr. Drug Targets"},{"key":"32888_CR39","doi-asserted-by":"crossref","unstructured":"Kaur, G. et al. Structural basis for the substrate specificity of helix pomatia AMP deaminase and a chimeric ADGF adenosine deaminase. Journal Biol. Chemistry 301, 1\u201311. (2025).","DOI":"10.1101\/2025.03.26.645602"},{"key":"32888_CR40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nchem.1894","volume":"6","author":"CM Rufo","year":"2014","unstructured":"Rufo, C. M. et al. Short peptides self-assemble to produce catalytic amyloids. Nat. Chem. 6, 303\u2013309 (2014).","journal-title":"Nat. Chem."},{"key":"32888_CR41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.aaf6846","volume":"356","author":"A Patel","year":"2017","unstructured":"Patel, A. et al. ATP as a biological hydrotrope. Science 356, 753\u2013756 (2017).","journal-title":"Science"},{"key":"32888_CR42","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1039\/D3SC03612J","volume":"14","author":"ER Kamski-Hennekam","year":"2023","unstructured":"Kamski-Hennekam, E. R., Huang, J., Ahmed, R. & Melacini, G. Toward a molecular mechanism for the interaction of ATP with alpha-synuclein. Chem. Sci. 14, 9933\u20139942 (2023).","journal-title":"Chem. Sci."},{"key":"32888_CR43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/ncb1620","volume":"9","author":"Z Zhang","year":"2007","unstructured":"Zhang, Z. et al. Regulated ATP release from astrocytes through lysosome exocytosis. Nat. Cell. Biol. 9, 945\u2013953 (2007).","journal-title":"Nat. Cell. Biol."},{"key":"32888_CR44","doi-asserted-by":"crossref","unstructured":"Watanabe, H. et al. Brain network and energy imbalance in parkinson\u2019s disease: linking ATP reduction and \u03b1-synuclein pathology. Front Mol. Neurosci 17, 1\u201311. (2025).","DOI":"10.3389\/fnmol.2024.1507033"},{"key":"32888_CR45","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.3390\/ijms23169212","volume":"23","author":"TA Strope","year":"2022","unstructured":"Strope, T. A., Birky, C. J. & Wilkins, H. M. The role of bioenergetics in neurodegeneration. Int. J. Mol. Sci. 23, 9212 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"32888_CR46","doi-asserted-by":"crossref","unstructured":"Saxena, U. Bioenergetics failure in neurodegenerative diseases: back to the future. Expert Opin. Therapeutic Targets 16, 351\u2013354. (2012).","DOI":"10.1517\/14728222.2012.664135"},{"key":"32888_CR47","doi-asserted-by":"publisher","unstructured":"Shields, L. Y., Mendelsohn, B. A. & Nakamura, K. Measuring ATP in Axons with FRET. in Techniques to Investigate Mitochondrial Function in Neurons 115\u2013131Humana Press, New York, NY, (2017). https:\/\/doi.org\/10.1007\/978-1-4939-6890-9_6","DOI":"10.1007\/978-1-4939-6890-9_6"},{"key":"32888_CR48","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2013.12.042","volume":"156","author":"V Rangaraju","year":"2014","unstructured":"Rangaraju, V., Calloway, N. & Ryan, T. A. Activity-driven local ATP synthesis is required for synaptic function. Cell 156, 825\u2013835 (2014).","journal-title":"Cell"},{"key":"32888_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11306-024-02181-4","volume":"20","author":"X Flores-Ponce","year":"2024","unstructured":"Flores-Ponce, X. & Velasco, I. Dopaminergic neuron metabolism: relevance for Understanding parkinson\u2019s disease. Metabolomics 20, 1\u201314 (2024).","journal-title":"Metabolomics"},{"key":"32888_CR50","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12640-022-00579-3","volume":"40","author":"U Naeem","year":"2022","unstructured":"Naeem, U. et al. Glycolysis: the next big breakthrough in parkinson\u2019s disease. Neurotox. Res. 40, 1707\u20131717 (2022).","journal-title":"Neurotox. Res."},{"key":"32888_CR51","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1172\/JCI129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai, R. et al. Enhancing Glycolysis attenuates parkinson\u2019s disease progression in models and clinical databases. J. Clin. Invest. 129, 4539\u20134549 (2019).","journal-title":"J. Clin. Invest."},{"key":"32888_CR52","doi-asserted-by":"crossref","first-page":"eadn6016","DOI":"10.1126\/sciadv.adn6016","volume":"10","author":"AC Kokotos","year":"2024","unstructured":"Kokotos, A. C. et al. Phosphoglycerate kinase is a central leverage point in parkinson\u2019s disease\u2013driven neuronal metabolic deficits. Sci. Adv. 10, eadn6016 (2024).","journal-title":"Sci. Adv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32888-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:05:15Z","timestamp":1769216715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32888-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32888"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32888-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2921"}}